Nxera Pharma Exercises Option to License Lucerastat in Japan and Selected Asian Markets
Nxera says it has exercised its option to license the Phase 3 Fabry disease therapy candidate lucerastat in Japan, South Korea, Taiwan and selected other markets.
Story updates
07:33:45 AM UTC
SquawkNews
Tokyo, Japan and Cambridge, UK, 28 October 2026 — Nxera Pharma Co., Ltd. ("Nxera" or the "Company"; TSE: 4565) today announces that it has exercised its option to license lucerastat from Idorsia Ltd ("Idorsia"; SIX: IDIA) and has entered into a co-development and commercialization agreement (the "A…